<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112382</url>
  </required_header>
  <id_info>
    <org_study_id>CL (1461)</org_study_id>
    <nct_id>NCT03112382</nct_id>
  </id_info>
  <brief_title>Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus</brief_title>
  <acronym>SLC30A8</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <brief_summary>
    <textblock>
      Study whether SLC30A8 rs13266634 polymorphism is associated with type 2 diabetes mellitus
      (T2DM) susceptibility in Egyptian patients and study effect of Zn supplementation on glycemic
      control in patients with type 2 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SLC30A8 rs13266634 polymorphism</measure>
    <time_frame>one year</time_frame>
    <description>genetic screening of SLC30A8 : solute carrier family 30 member 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum zinc</measure>
    <time_frame>at base line</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in fasting and 2hr post prandial blood glucose at three months</measure>
    <time_frame>at base line and after three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in HbA1c at three months</measure>
    <time_frame>base line and three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in lipid profile at three months</measure>
    <time_frame>base line and three months</time_frame>
    <description>lipid profile: total cholesterol, triglyceride, HDL, LDL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in fasting serum insulin at three months</measure>
    <time_frame>baseline and three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in ALT level at three months</measure>
    <time_frame>baseline and three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Mg</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatinine level</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Iron</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in total serum Calcium at three months</measure>
    <time_frame>baseline and three months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>zinc supplement plus vitamin A and E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will be receiving zinc supplement plus vitamin A and E for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin A and E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will be receiving equivalent dose of vitamin A and E only for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no vitamins</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will be observed for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zinc supplement plus vitamin A and E</intervention_name>
    <arm_group_label>zinc supplement plus vitamin A and E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin A and E</intervention_name>
    <arm_group_label>vitamin A and E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of type 2 diabetes mellitus.

          -  Age between 20 and 64 years.

          -  BMI &lt; 40 kg/m2.

          -  On fixed oral hypoglycemic dosage for at least 3 months.

          -  Normal serum creatinine (0.5 to 1.3 mg/dL) with no clinical evidence suggestive kidney
             disease.

          -  Normal liver function tests (ALT 7 to 55 U/L, and albumin Ëƒ 3.5 g/dL).

        Exclusion Criteria:

          -  Those diagnosed of osteomalacia, chronic alcoholics. Patients with type 1 Diabetes
             Mellitus.

          -  Those who were taking multivitamin containing zinc or magnesium or any sort of mineral
             supplements in the previous three months or hormone replacement therapy (estrogen,
             progesterone) or chelating therapy such as penicillamine, or anticonvulsant
             (phenytoin, valproate).

          -  Those with a history of recent surgery or with concurrent acute illness including
             infectious disease, trauma, inflammatory bowel disease, malignancy, and active
             immunological diseases, using corticosteroids.

          -  Pregnant or intend to be pregnant for t least 3 months or lactating women.

          -  Those who were receiving insulin preparations as a part of diabetes management.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>theoutpatient clinics, department of internal medicine, Cairo University teaching hospitals,</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>August 6, 2017</last_update_submitted>
  <last_update_submitted_qc>August 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Eman Said</investigator_full_name>
    <investigator_title>Assisstant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

